
ABOUT US
Amygo Biotechnologies is a novel medical device company that stands to revolutionize Alzheimer’s Disease (AD) treatment and prevention.
Our Mission
Amygo Biotechnologies is committed to providing an easy-to-use product with a comfortable and familiar experience for our customers. We are committed to fostering UN development goals 3 (Health and Well-being) and 5 (Gender-Equality) as according to the WHO, “women are disproportionately impacted by AD”, and provide up-to 70% of care-hours.
Our Values
Our product and company have the purpose of extending the quality (and hopefully length) of people's lives, by helping to prevent and heal AD. As we have personal experience as family members and caretakers of people with AD, we are committed to the health and well being of our customers, and to giving them the highest caliber of device possible.
Our Founders

Tiffany Kurland
CEO, Founder with a background in Molecular Biology, Health Sciences, and Business.
Tiffany Kurland has been researching AD since she was 8 years old when her grandfather passed away from dementia. She has had 6 more family members pass away from dementia since then. Tiffany studied molecular biology and biochemistry in the hopes of finding a cure to this disease, and so far, this is the best she can find. She first invented this device at 12 years old while brushing her teeth and thinking about how the vibrations of the electric toothbrush helped to get rid of plaque in the mouth, why can't we do that for plaque in the brain. Through much extensive research (12 more years of it), she has discovered her hypothesis was correct.

Max Zou
CSO, Co-Founder with a background in Electrical Engineering and Mechatronics Systems Engineering.
Max is an electrical engineer, with a background in electronics in industrial appliances and robotics. Max has enjoyed robotics and engineering as a hobby since early elementary school, and eventually worked at Tesla motors as an electrical design engineer. While seeking an impactful project to work on in university, he joined Tiffany on the Amygo project.
OUR SCIENCE
About the Problem
Alzheimer's is a progressive neurological disease that strips away people's memories, families, and lives. AD is the primary cause of disability in the elderly, and 7th leading cause of death globally (WHO, 2025).
1/9 over 50, and 1/3 over 85 suffer from AD (WHO, 2025). There are limited treatments, and no cure.
The Science
AD is caused by amyloid plaque and tau tangles, which result in brain cell deterioration (Alzheimer's Society, 2025).
Our device is based on breakthrough novel research, which has only existed for a decade. The Amygo breaks up plaque and tangles, while stimulating stem cells to regrow neurons.
About Our Solution
Our solution, The Amygo, is a patent pending: at-home, non-invasive, low-risk, Class-II wearable medical device (same official risk class as an electric toothbrush); which uses electromagnetic and acoustic vibrations to treat AD.
At-Home
Convenient treatment from the comfort of your home
Non-Invasive
Safe treatment without surgical procedures
Low-Risk
Class-II medical device with minimal risk
Innovative
Electromagnetic and acoustic vibration technology
Amygo vs. Competitors
Non-invasive | Side Effects* | Efficiency* | At-Home | Preventative | |
---|---|---|---|---|---|
Y | None | Strong | Y | Y | |
Pharmaceuticals | N | High | Weak | Y | N |
Ultrasonic | N | High | Moderate | N | N |
EEG | Y | Low | Weak | Y | Y |